Quigley to study anti-inflammatory compound QR-440 in arthritic dogs

By Angela McDaniels

Seattle, Jan. 31 - Quigley Pharma Inc. said it has received an additional Investigational New Animal Drug number from the Center for Veterinary Medicine of the Food and Drug Administration to study its naturally derived, broad-spectrum anti-inflammatory compound QR-440 in dogs with arthritis.

"Further development and testing of this unique compound as a potential drug for veterinary use is both important for dogs and their owners [and supports] our ongoing research process to develop this compound for human use," chief operations officer Richard Rosenbloom said in a company news release.

Canine arthritis affects 70% to 80% of dogs in certain breeds, according to the release. Rheumatoid arthritis occurs most commonly in toy or small breeds, generally between five and six years of age.

Quigley Pharma develops naturally derived pharmaceutical compounds. It is a wholly owned subsidiary of The Quigley Corp., a Doylestown, Pa.-based developer and marketer of diversified health products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.